From GlobeNewswire: 2024-07-30 13:00:00

The Hepatic Tumor market is on the rise with 75+ companies actively developing pipeline therapies for liver cancer treatment. Risk factors like chronic viral hepatitis and NAFLD are driving the market growth. Promising therapies like Namodenoson and MTL CEBPA are in clinical trials. Recent milestones include Carisma’s development candidate targeting hepatocellular carcinoma and Ascelia Pharma’s successful Phase III study with Orviglance.

Innovative companies like Can Fite Biopharma, MiNA Therapeutics, and Shanghai Junshi Biosciences are advancing hepatic tumor pipeline therapies. Various drugs targeting different mechanisms of action are in different phases of clinical trials. Important collaborations, like the one between Carisma Therapeutics Inc. and Moderna, are driving progress in liver cancer treatments. Bristol Myers Squibb’s acquisition of RayzeBio for $4.1 billion signals a strengthening hepatic tumor pipeline market.

A strategic partnership between Target RWE and AASLD has enrolled 75,000 patients in a real-world registry for chronic liver diseases. The hepatic tumor pipeline report by DelveInsight provides detailed insights into emerging therapies for liver cancer, including key companies like Genmab and Bio-Thera Solutions working on novel treatments. The report covers therapy types, clinical stages, mechanisms of action, and opportunities in the hepatic tumor treatment landscape.

Liver tumors, such as hepatocellular carcinoma and cholangiocarcinoma, can arise from various factors like chronic liver disease, obesity, and exposure to toxins. Symptoms include abdominal pain, weight loss, and jaundice. Diagnosis involves imaging studies and blood tests. Treatment options range from surgery to targeted therapy. Early detection is crucial for better outcomes in liver tumor patients.

The hepatic tumor pipeline is expanding with innovative therapies like Fostroxacitabine bralpamide and SRF388 in development. Companies like Coherus Biosciences and Eureka Therapeutics are pushing the boundaries in liver cancer treatment. The report by DelveInsight provides a comprehensive overview of hepatic tumor therapies, from discovery to Phase III stages, highlighting potential game-changers in the market.



Read more at GlobeNewswire: Hepatic Tumor Clinical Trial Pipeline Experiences Momentum: